Evidence map›Paper›PMID 40936411›Full record

ArticleAdvanced healthcare materials2026

Thiolated Hyaluronic Acid: A Gateway for Targeted Killing of Staphylococcus aureus on the Race for Surface Colonization.

Mariana Blanco Massani, Susanne Meile, Annabelle Knoll, David Gintsburg, Ilaria Polidori, Anna Seybold, Débora C Coraça-Huber, Martin J Loessner, Gergely Kali, Mathias Schmelcher and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mariana Blanco MassaniCentre for Chemistry and Biomedicine (CCB), Department of Pharmaceutical Technology, Institute of Pharmacy, University of Innsbruck, Innrain 80/82, Innsbruck, 6020, Austria.ORCID 0000-0002-5053-6378
Susanne MeileInstitute of Food, Nutrition and Health, ETH Zürich, Schmelzbergstrasse 7, Zürich, 8092, Switzerland.ORCID 0000-0001-8786-7157
Annabelle KnollCentre for Chemistry and Biomedicine (CCB), Department of Pharmaceutical Technology, Institute of Pharmacy, University of Innsbruck, Innrain 80/82, Innsbruck, 6020, Austria.
David GintsburgCentre for Chemistry and Biomedicine (CCB), Department of Pharmaceutical Technology, Institute of Pharmacy, University of Innsbruck, Innrain 80/82, Innsbruck, 6020, Austria.ORCID 0009-0003-5625-4173
Ilaria PolidoriCentre for Chemistry and Biomedicine (CCB), Department of Pharmaceutical Technology, Institute of Pharmacy, University of Innsbruck, Innrain 80/82, Innsbruck, 6020, Austria.ORCID 0009-0007-7059-7200
Anna SeyboldDepartment of Zoology, University of Innsbruck, Innsbruck, 6020, Austria.ORCID 0000-0002-2237-3989
Débora C Coraça-HuberBiofilm Lab, Experimental Orthopedics, University Hospital for Orthopaedics and Traumatology, Medical University Innsbruck, Müllerstrasse 44, 1. Floor, Innsbruck, 6020, Austria.ORCID 0000-0001-7664-5989
Martin J LoessnerFaculty of Chemistry, Nanoengineering of Functional Polymeric Materials Group, Jagiellonian University, Gronostajowa 2, Krakow (Krakow-Podgorze), 30-387, Poland.ORCID 0000-0002-8162-2631
Gergely KaliCentre for Chemistry and Biomedicine (CCB), Department of Pharmaceutical Technology, Institute of Pharmacy, University of Innsbruck, Innrain 80/82, Innsbruck, 6020, Austria.ORCID 0000-0002-8538-6971
Mathias SchmelcherFaculty of Chemistry, Nanoengineering of Functional Polymeric Materials Group, Jagiellonian University, Gronostajowa 2, Krakow (Krakow-Podgorze), 30-387, Poland.ORCID 0000-0003-3535-3861
Szczepan ZapotocznyFaculty of Chemistry, Nanoengineering of Functional Polymeric Materials Group, Jagiellonian University, Gronostajowa 2, Krakow (Krakow-Podgorze), 30-387, Poland.ORCID 0000-0001-6662-7621
Andreas Bernkop-SchnürchCentre for Chemistry and Biomedicine (CCB), Department of Pharmaceutical Technology, Institute of Pharmacy, University of Innsbruck, Innrain 80/82, Innsbruck, 6020, Austria.ORCID 0000-0003-4187-8277

Funding

European Union's Horizon 2020 101025065
6 · The paper itself

Abstract

Hyaluronic acid (HA) is degraded by Staphylococcal hyaluronate lyase (Hysa) and mammalian hyaluronidase (Hyal). Thiolated HA (HAMS) is used as a targeted gateway for Staphylococcus aureus killing while enhancing the previous M23 endolysin-polyphosphate (M23-PP NPs) enzyme-responsive nanoparticle formulation. Synthesis of HAMS and characterization for nuclear magnetic resonance, solubility, thiol content, pKa, and degradation by Hysa and Hyal are presented. Nanoparticles prepared via ionotropic gelation between M23-PP NPs and either HAMS or HA yield M23-PP/HAMS or M23-PP/HA NPs, respectively. Their characterization includes size, zeta potential, morphology, release profiles, safety, targeted release, and efficacy. HAMS with a thiol content of 250.18 ± 90.32 µmol g

Indexed as

Anti-Bacterial AgentsHyaluronic AcidStaphylococcus aureusSulfhydryl CompoundsAnimalsHyaluronoglucosaminidaseMiceNanoparticlesPolyphosphatesPolysaccharide-LyasesAnti-Bacterial Agentshyaluronate lyaseHyaluronic AcidHyaluronoglucosaminidasePolyphosphatesPolysaccharide-LyasesSulfhydryl Compoundsenzyme‐responsivephage endolysinsStaphylococcus aureustargeted drug deliverythiolated hyaluronic acid

Identifiers

PMID40936411
PMCPMC12805623

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.